Rokote Laboratories Finland Ltd., a vaccine development company focusing on a second-generation Covid-19 vaccine, has partnered with Exothera S.A. to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.
 
Exothera will finetune the industrialization of the FINCOVAC 2.0 process and manufacture clinical material for Phase I/II trials.

Bringing FINCoVac 2.0 to Clinical Trials More Quickly

FINCoVac 2.0 is designed to address the most critical current coronavirus variants and it is based on adenoviral vector gene transfer technology. The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce an immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other coronavirus vaccines.
 
Exothera specializes in the industrialization of vaccine and gene therapy processes with deep knowledge of modern scalable bioreactors, downstream process technologies and GMP manufacturing. Exothera offers a full-service model where it manages all the elements of the product development value chain, from process development to manufacturing. This single partner approach will allow Rokote Laboratories to enter clinical trials more quickly.
 
Hanna Lesch, chief technology officer at Exothera, said, “Exothera’s leading viral manufacturing expertise fits perfectly with Rokote Laboratories’ needs. As a Finn, I am proud to be part of the Finnish FINCoVac vaccine program. We are excited to continue supporting the ongoing fight against the coronavirus pandemic.”
 
Erkko Ylösmäki, director, Research and Development at Rokote Laboratories Finland commented, ”Exothera’s manufacturing capabilities, the full-service model, and the outstanding commitment to rapid manufacturing of our vaccine for the Phase I/II trials is everything we were looking for from a CDMO. We are excited to start this collaboration to address the global need for an easy-to-administer COVID-19 vaccine that can not only prevent the disease but can also prevent those vaccinated from further transmitting the SARS-CoV-2 virus.”